Patents by Inventor Taketoshi Okubo
Taketoshi Okubo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20110227976Abstract: The invention provides an ink jet recording ink containing a self-dispersion pigment to a surface of which an anionic functional group represented by the following general formula (1) is bonded directly or through another atomic group, an ammonium salt of an organic carboxylic acid, water, and a water-soluble compound having a hydrophilicity-hydrophobicity coefficient of 0.Type: ApplicationFiled: January 14, 2010Publication date: September 22, 2011Applicant: CANON KABUSHIKI KAISHAInventors: Shoji Koike, Ikuo Nakazawa, Taketoshi Okubo, Akira Kuriyama, Masayuki Ikegami, Atsuhito Yoshizawa
-
Publication number: 20110205285Abstract: An inkjet recording ink having a surface tension of 34 mN/m or more is provided. The inkjet recording ink contains an anionic self-dispersion pigment having an anionic functional group, a salt, and a water-soluble compound having a hydrophilicity/hydrophobicity coefficient of 0.26 or more. The ink contains a larger amount of cesium ion than the amount of the anionic functional group. The hydrophilicity/hydrophobicity coefficient is defined by equation (A).Type: ApplicationFiled: February 23, 2011Publication date: August 25, 2011Applicant: CANON KABUSHIKI KAISHAInventors: Taketoshi Okubo, Atsuhito Yoshizawa, Shoji Koike
-
Publication number: 20110137031Abstract: An object of the present invention is to provide an antagonist against CRF receptors which is effective as a therapeutic or prophylactic agent for diseases in which CRF is considered to be involved, such as depression, anxiety, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorder, hypertension, gastral diseases, drug dependence, epilepsy, cerebral infarction, cerebral ischemia, cerebral edema, cephalic external wound, inflammation, immunity-related diseases, alpecia, irritable bowel syndrome, sleep disorders, dermatitides, schizophrenia, pain, etc. A pyrrolopyrimidine or pyrrolotriazine derivative substituted with a carbamoyl group represented by the following formula [I]: has a high affinity for CRF receptors and is effective against diseases in which CRF is considered to be involved.Type: ApplicationFiled: January 6, 2005Publication date: June 9, 2011Applicant: TAISHO PHARMACEUTICAL CO., LTD.Inventors: Atsuro Nakazato, Taketoshi Okubo, Dai Nozawa, Tomoko Tamita, Ludo E.J. Kennis
-
Publication number: 20110130364Abstract: An object of the present invention is to provide an antagonist against CRF receptors which is effective as a therapeutic or prophylactic agent for diseases in which CRF is considered to be involved, such as depression, anxiety, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorder, hypertension, gastric diseases, drug dependence, epilepsy, cerebral infarction, cerebral ischemia, cerebral edema, cephalic external wound, inflammation, immunity-related diseases, alopecia, irritable bowel syndrome, sleep disorders, epilepsy, dermatitides, schizophrenia, etc. This problem can be solved with a pyrrolopyrimidine or pyrrolopyridine derivative substituted with a cyclic amino group represented by formula [I] below which has a high affinity for CRF receptors and is effective against diseases in which CRF is considered to be involved.Type: ApplicationFiled: November 22, 2010Publication date: June 2, 2011Applicant: TAISHO PHARMACEUTICAL CO., LTD.Inventors: Atsuro NAKAZATO, Taketoshi Okubo, Dai Nozawa, Mikako Yamaguchi, Tomoko Tamita, Ludo E.J. Kennis, Marcel F.L. De Bruyn, Jean-Pierre A.M. Bongartz, Frans M.A. Van Den Keybus, Yves E.M. Van Roosbroeck, Marcel G.M. Luyckx, Robert J.M. Hendrickx
-
Patent number: 7951811Abstract: [PROBLEM TO BE SOLVED] An object of the present invention is to provide an antagonist against CRF receptors and/or an agonist for ? receptors which is effective as a therapeutic or prophylactic agent for diseases in which CRF is considered to be involved, such as depression, anxiety, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorder, hypertension, gastrointestinal diseases, drug dependence, cerebral infarction, cerebral ischemia, cerebral edema, cephalic external wound, inflammation, immunity-related diseases, alopecia, irritable bowel syndrome, sleep disorders, epilepsy, dermatitides, schizophrenia, pain, etc. [SOLUTION] A pyrrolopyrimidine or pyrrolopyridine derivative substituted with a cyclic amino group represented by the following a [I] has a high affinity for CRF receptors and/or ? receptors, and is effective against diseases in which CRF is considered to be involved.Type: GrantFiled: June 24, 2005Date of Patent: May 31, 2011Assignee: Taisho Pharmaceutical Co., Ltd.Inventors: Atsuro Nakazato, Taketoshi Okubo, Dai Nozawa, Tomoko Tamita, Ludo E. J. Kennis
-
Publication number: 20110124862Abstract: [Problem to be Solved] An object of the present invention is to provide an antagonist against CRF receptors and/or an agonist for ? receptors which is effective as a therapeutic or prophylactic agent for diseases in which CRF is considered to be involved, such as depression, anxiety, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorder, hypertension, gastrointestinal diseases, drug dependence, cerebral infarction, cerebral ischemia, cerebral edema, cephalic external wound, inflammation, immunity-related diseases, alopecia, irritable bowel syndrome, sleep disorders, epilepsy, dermatitides, schizophrenia, pain, etc. [Solution] A pyrrolopyrimidine or pyrrolopyridine derivative substituted with a cyclic amino group represented by the following formula [I] has a high affinity for CRF receptors and/or ? receptors, and is effective against diseases in which CRF is considered to be involved.Type: ApplicationFiled: February 1, 2011Publication date: May 26, 2011Applicant: TAISHO PHARMACEUTICAL CO., LTD.Inventors: Atsuro NAKAZATO, Taketoshi Okubo, Dai Nozawa, Tomoko Tamita, Ludo E.J. Kennis
-
Patent number: 7932259Abstract: An object of the present invention is to provide an antagonist against CRF receptors which is effective as a therapeutic or prophylactic agent for diseases in which CRF is considered to be involved, such as depression, anxiety, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorder, hypertension, gastric diseases, drug dependence, epilepsy, cerebral infarction, cerebral ischemia, cerebral edema, cephalic external wound, inflammation, immunity-related diseases, alopecia, irritable bowel syndrome, sleep disorders, epilepsy, dermatitides, schizophrenia, etc. This problem can be solved with a pyrrolopyrimidine or pyrrolopyridine derivative substituted with a cyclic amino group represented by formula [I] below which has a high affinity for CRF receptors and is effective against diseases in which CRF is considered to be involved.Type: GrantFiled: April 21, 2008Date of Patent: April 26, 2011Assignee: Taisho Pharmaceutical Co., Ltd.Inventors: Atsuro Nakazato, Taketoshi Okubo, Dai Nozawa, Mikako Yamaguchi, Tomoko Tamita, Ludo E. J. Kennis, Marcel F. L. De Bruyn, Jean-Pierre A. M. Bongartz, Frans M. A. Van Den Keybus, Yves E. M. Van Roosbroeck, Marcel G. M. Luyckx, Robert J. M. Hendrickx
-
Publication number: 20090291940Abstract: Disclosed is an aminopyrrolidine compound represented by the formula [I] or a pharmaceutically acceptable salt thereof. The compound or the salt is useful as a prophylactic/therapeutic agent for mode disorder such as depression, anxiety disorder, anorexia, cachexia, pain and drug dependence, whose action relies on the MC4 receptor antagonistic effect.Type: ApplicationFiled: March 30, 2007Publication date: November 26, 2009Applicants: Taisho Pharmaceutical Co., Ltd., Nissan Chemical Industries, Ltd.Inventors: Taketoshi Okubo, Toshihito Kumagai, Takaaki Ishii, Toshio Nakamura, Kumi Abe, Yuri Amada, Tomoko Ishizaka, Xiang-Min Sun, Yoshinori Sekiguchi, Shigetada Sasako, Takanori Shimizu, Takayuki Nagatsuka
-
Patent number: 7557111Abstract: An object of the present invention is to provide an antagonist against CRF receptors which is effective as a therapeutic or prophylactic agent for diseases in which CRF is considered to be involved, such as depression, anxiety, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorder, hypertension, gastral diseases, drug dependence, epilepsy, cerebral infarction, cerebral ischemia, cerebral edema, cephalic external wound, inflammation, immunity-related diseases, alpecia, irritable bowel syndrome, sleep disorders, epilepsy, dermatitides, schizophrenia, etc. A thienopyrimidine or thienopyridine derivative substituted with a cyclic amino group represented by the following formula [I]: has a high affinity for CRF receptors and is effective against diseases in which CRF is considered to be involved.Type: GrantFiled: January 6, 2005Date of Patent: July 7, 2009Assignee: Taisho Pharmaceutical Co., Ltd.Inventors: Atsuro Nakazato, Taketoshi Okubo, Dai Nozawa, Tomoko Tamita, Ludo E. J. Kennis
-
Publication number: 20090111835Abstract: An object of the present invention is to provide an antagonist against CRF receptors which is effective as a therapeutic or prophylactic agent for diseases in which CRF is considered to be involved, such as depression, anxiety, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorder, hypertension, gastral diseases, drug dependence, epilepsy, cerebral infarction, cerebral ischemia, cerebral edema, cephalic external wound, inflammation, immunity-related diseases, alpecia, irritable bowel syndrome, sleep disorders, dermatitides, schizophrenia, pain, etc. A thienopyrimidine or thienopyridine derivative substituted with a cyclic amino group represented by the following formula [I]: has a high affinity for CRF receptors and is effective against diseases in which CRF is considered to be involved.Type: ApplicationFiled: December 18, 2008Publication date: April 30, 2009Applicant: TAISHO PHARMACEUTICAL CO., LTD.Inventors: Atsuro Nakazato, Taketoshi Okubo, Dai Nozawa, Tomoko Tamita, Ludo E.J. Kennis
-
Publication number: 20080318923Abstract: It is intended to provide a drug which is efficacious against pathological conditions relating to arginine-vasopressin V1b receptor. More particularly speaking, it is intended to provide a drug which has a therapeutic or preventive effect on depression, anxiety, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorders, hypertension, digestive diseases, drug addiction, epilepsy, brain infarction, brain ischemia, brain edema, head injury, inflammation, immune diseases, alopecia and so on. As the results of intensive studies, a novel 1,3-dihydro-2H-indol-2-one compound and a pyrrolidin-2-one compound fused with a heteroaromatic ring, which are highly selective antagonists of arginine-vasopressin V1b receptor, have high metabolic stabilities and show favorable brain penetration and high plasma concentrations, are found, thereby achieving the above objective.Type: ApplicationFiled: January 30, 2006Publication date: December 25, 2008Applicant: TAISHO PHARMACEUTICAL CO., LTD.Inventors: Yoshinori Sekiguchi, Takeshi Kuwada, Masato Hayashi, Dai Nozawa, Yuri Amada, Tsuyoshi Shibata, Shuji Yamamoto, Hiroshi Ohta, Taketoshi Okubo, Takeshi Koami
-
Publication number: 20080287397Abstract: An object of the present invention is to provide an antagonist against CRF receptors which is effective as a therapeutic or prophylactic agent for diseases in which CRF is considered to be involved, such as depression, anxiety, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorder, hypertension, gastric diseases, drug dependence, epilepsy, cerebral infarction, cerebral ischemia, cerebral edema, cephalic external wound, inflammation, immunity-related diseases, alopecia, irritable bowel syndrome, sleep disorders, epilepsy, dermatitides, schizophrenia, etc. This problem can be solved with a pyrrolopyrimidine or pyrrolopyridine derivative substituted with a cyclic amino group represented by formula [I] below which has a high affinity for CRF receptors and is effective against diseases in which CRF is considered to be involved.Type: ApplicationFiled: April 21, 2008Publication date: November 20, 2008Applicant: TASHO PHARMACEUTICAL CO., LTD.Inventors: Atsuro NAKAZATO, Taketoshi Okubo, Dai Nozawa, Mikako Yamaguchi, Tomoko Tamita, Ludo E.J. Kennis, Marcel F.L. De Bruyn, Jean-Pierre A.M. Bongartz, Frans M.A. Van Den Keybus, Yves E.M. Van Roosbroeck, Marcel G.M. Luyckx, Robert J.M. Hendrickx
-
Publication number: 20080280928Abstract: [PROBLEM TO BE SOLVED] An object of the present invention is to provide an antagonist against CRF receptors and/or an agonist for ? receptors which is effective as a therapeutic or prophylactic agent for diseases in which CRF is considered to be involved, such as depression, anxiety, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorder, hypertension, gastrointestinal diseases, drug dependence, cerebral infarction, cerebral ischemia, cerebral edema, cephalic external wound, inflammation, immunity-related diseases, alopecia, irritable bowel syndrome, sleep disorders, epilepsy, dermatitides, schizophrenia, pain, etc. [SOLUTION] A pyrrolopyrimidine or pyrrolopyridine derivative substituted with a cyclic amino group represented by the following a [I] has a high affinity for CRF receptors and/or ? receptors, and is effective against diseases in which CRF is considered to be involved.Type: ApplicationFiled: June 24, 2005Publication date: November 13, 2008Applicant: TAISHO PHARMACEUTICAL CO., LTD.Inventors: Atsuro Nakazato, Taketoshi Okubo, Dai Nozawa, Tomoko Tamita, Ludo E.J. Kennis
-
Patent number: 7365078Abstract: An object of the present invention is to provide an antagonist against CRF receptors which is effective as a therapeutic or prophylactic agent for diseases in which CRF is considered to be involved, such as depression, anxiety, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorder, hypertension, gastral diseases, drug dependence, epilepsy, cerebral infarction, cerebral ischemia, cerebral edema, cephalic external wound, inflammation, immunity-related diseases, alpecia, irritable bowel syndrome, sleep disorders, dermatitides, schizophrenia, pain, etc.Type: GrantFiled: January 6, 2005Date of Patent: April 29, 2008Assignee: Taisho Pharmaceutical Co., Ltd.Inventors: Atsuro Nakazato, Taketoshi Okubo, Dai Nozawa, Tomoko Tamita, Ludo E. J. Kennis
-
Publication number: 20070293670Abstract: [PROBLEM TO BE SOLVED]An object of the present invention is to provide an antagonist against CRF receptors which is effective as a therapeutic or prophylactic agent for diseases in which CRF is considered to be involved, such as depression, anxiety, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorder, hypertension, gastrointestinal diseases, drug dependence, cerebral infarction, cerebral ischemia, cerebral edema, cephalic external wound, inflammation, immunity-related diseases, alopecia, irritable bowel syndrome, sleep disorders, epilepsy, dermatitides, schizophrenia, pain, etc. [SOLUTION]A pyrrolopyrimidine or pyrrolopyridine derivative substituted with tetrahydropyridine represented by the following formula [I]: has a high affinity for CRF receptors and is effective against diseases in which CRF is considered to be involved.Type: ApplicationFiled: June 24, 2005Publication date: December 20, 2007Applicant: TAISHO PHARMACEUTICAL CO., LTD.Inventors: Atsuro Nakazato, Taketoshi Okubo, Dai Nozawa, Ludo Kennis, Marcel De Bruyn
-
Publication number: 20070254898Abstract: [Problem to be Solved] An object of the present invention is to provide an antagonist against CRF receptors which is effective as a therapeutic or prophylactic agent for diseases in which CRF is considered to be involved, such as depression, anxiety, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorder, hypertension, gastral diseases, drug dependence, epilepsy, cerebral infarction, cerebral ischemia, cerebral edema, cephalic external wound, inflammation, immunity-related diseases, alpecia, irritable bowel syndrome, sleep disorders, epilepsy, dermatitides, schizophrenia, etc. [Solution] A thienopyrimidine or thienopyridine derivative substituted with a cyclic amino group represented by the following formula [I]: has a high affinity for CRF receptors and is effective against diseases in which CRF is considered to be involved.Type: ApplicationFiled: January 6, 2005Publication date: November 1, 2007Inventors: Atsuro Nakazato, Taketoshi Okubo, Dai Nozawa, Tomoko Tamita, Ludo Kennis
-
Publication number: 20070060602Abstract: An object of the present invention is to provide an antagonist against CRF receptors which is effective as a therapeutic or prophylactic agent for diseases in which CRF is considered to be involved, such as depression, anxiety, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorder, hypertension, gastral diseases, drug dependence, epilepsy, cerebral infarction, cerebral ischemia, cerebral edema, cephalic external wound, inflammation, immunity-related diseases, alpecia, irritable bowel syndrome, sleep disorders, dermatitides, schizophrenia, pain, etc. A triaza-cyclopenta[cd]indene derivative represented by the following formula [I]: has a high affinity for CRF receptors and is effective against diseases in which CRF is considered to be involved.Type: ApplicationFiled: January 6, 2005Publication date: March 15, 2007Inventors: Atsuro Nakazato, Taketoshi Okubo, Dai Nozawa, Tomoko Tamita, Ludo Kennis
-
Patent number: 6949552Abstract: There are provided a therapeutic preparation for anxiety neurosis or depression which comprises a MC4 receptor antagonist as an effective ingredient; and a piperazine derivative represented by Formula [1]: [wherein Ar1 is a phenyl group, a substituted phenyl group, a naphthyl group or a substituted naphthyl group; Ar2 is a naphthyl group, a substituted naphthyl group, a quinolyl group, a group represented by the formula: (wherein R4 is a hydrogen atom or a halogen atom; and X—Y is CH—NH, CH—O, CH—S or N—O) or a group represented by the formula: (wherein R5 is a hydrogen atom, a hydroxyl group or a C1-10 alkoxy group); R1 is a hydrogen atom, a C1-10 alkyl group, a C3-8 cycloalkyl group, a C3-10 alkenyl group, a phenyl group, a 1-cyanoethyl group, a pyrimidin-2-yl group or an amidyl group; R2 and R3 are the same or different, and are each a hydrogen atom or a C1-10 alkyl group; A-B is N—CH2, CH—CH2, C(OH)—CH2 or C?CH; T1 is a single bond, —N(R6)— (wherein R6 is a hydrogen atom or a C1-10 alkyl groupType: GrantFiled: June 27, 2001Date of Patent: September 27, 2005Assignee: Taisho Pharmaceutical Co., Ltd.Inventors: Atsuro Nakazato, Shigeyuki Chaki, Taketoshi Okubo, Shin-ichi Ogawa, Takaaki Ishii
-
Publication number: 20050209253Abstract: An object of the present invention is to provide an antagonist against CRF receptors which is effective as a therapeutic or prophylactic agent for diseases in which CRF is considered to be involved, such as depression, anxiety, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorder, hypertension, gastric diseases, drug dependence, epilepsy, cerebral infarction, cerebral ischemia, cerebral edema, cephalic external wound, inflammation, immunity-related diseases, alopecia, irritable bowel syndrome, sleep disorders, epilepsy, dermatitides, schizophrenia, etc. [Solution] A pyrrolopyrimidine or pyrrolopyridine derivative substituted with a cyclic amino group represented by the following formula [I]: has a high affinity for CRF receptors and is effective against diseases in which CRF is considered to be involved.Type: ApplicationFiled: December 24, 2003Publication date: September 22, 2005Inventors: Atsuro Nakazato, Taketoshi Okubo, Dai Nozawa, Mikato Yamaguchi, Tomoko Tamita, Ludo Kennis, Marcel De Bruyn, Jean-Pierre Bongartz, Frans Van Den Keybus, Yves Van Roosbroeck, Marcel Luyckx, Robert Hendrickx
-
Patent number: 6894168Abstract: Carbamoyl tetrahydropyridine derivatives represented by the formula: [in the formula, R1 and R2 are identical or different, and each represents a hydrogen atom, a C1-C5 alkyl group, or the like; Y1—Y2 represents (R4)C?C(R5), (R6)C?N, N?N, (R7) N—CO, or N?C(R8); X1, X2, and X3 are identical or different, and each represents a hydrogen atom, a halogen atom, or the like; R3, R4, R5, and R6 are identical or different, and each represents a hydrogen atom or an alkyl group; R7 represents a hydrogen atom, a C1-C5 alkyl group, or the like; and R8 represents a hydrogen atom or a carbamoyl group] or a pharmaceutically acceptable salt thereof, and intermediates for the preparation thereof are provided. The derivatives described above are effective for diseases which are believed to involve CRF.Type: GrantFiled: January 21, 2003Date of Patent: May 17, 2005Assignee: Taisho Pharmaceutical Co., Ltd.Inventors: Atsuro Nakazato, Taketoshi Okubo, Toshihito Kumagai, Kazuyuki Tomisawa